Reaction
Metamorphopsia reporting signals
As of the last recalculation, Metamorphopsia appears in 1,812 FAERS reports alongside 24 co-occurring drug terms. The strongest observed disproportionality signal is RANIBIZUMAB (PRR 98.2).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ranibizumab | 202 | 98.2 | 99.0 |
| Aflibercept | 149 | 59.7 | 60.0 |
| Faricimab | 20 | 28.7 | 28.7 |
| Encorafenib | 12 | 14.0 | 14.0 |
| Cenobamate | 9 | 12.4 | 12.5 |
| Lifitegrast | 15 | 10.6 | 10.6 |
| Prednisolone Acetate | 9 | 10.0 | 10.0 |
| Carboxymethylcellulose Sodium | 8 | 9.8 | 9.8 |
| Bevacizumab | 99 | 9.7 | 9.7 |
| Tobramycin Solution | 10 | 9.6 | 9.6 |
| Tobramycin Sulfate | 10 | 9.3 | 9.3 |
| Doxyclycline Hyclate | 13 | 8.8 | 8.8 |
| Triamcinolone Acetonide Ointment Usp, 0.05% | 17 | 8.4 | 8.4 |
| Brinzolamide | 6 | 8.0 | 8.0 |
| Brimonidine Tartrate | 12 | 7.8 | 7.8 |
| Brivaracetam | 6 | 7.7 | 7.7 |
| Triamcinolone Acetonide | 19 | 7.1 | 7.1 |
| Latanoprost | 30 | 6.9 | 7.0 |
| Travoprost | 5 | 6.7 | 6.7 |
| Timolol | 6 | 5.7 | 5.7 |
| Tobramycin | 11 | 5.3 | 5.3 |
| Fingolimod Hcl | 37 | 5.0 | 5.0 |
| Trametinib | 8 | 3.8 | 3.8 |
| Vigabatrin | 3 | 2.4 | 2.4 |